PanGIA Biotech, a US-based biotechnology company, is finalizing a three-year, prospective, multicenter clinical study on prostate cancer liquid biopsy and is preparing to launch additional clinical studies for multi-cancer early detection using the PanGIA® Liquid Biopsy Platform. This platform utilizes urine-based true liquid biopsy technology, integrating artificial intelligence (AI) for diagnosing, monitoring, and managing cancers earlier, with the goal of saving lives through improved availability and scalability in cancer diagnostics.
The company received IRB approval in 2020 and launched a novel AI-integrated urine-based liquid biopsy study, recruiting urologists from US-based academic and community practices to enroll men scheduled for prostate biopsy. The results of this study are pending publication.
Building on the high sensitivity and specificity observed in the prostate study, PanGIA Biotech is now expanding its platform to include follow-on studies in ten additional cancer types: breast, ovarian, lung, renal, bladder, colorectal, stomach, pancreas, liver, and brain. The company plans to recruit experienced medical professionals across the United States as clinical study sites and will list the study on ClinicalTrials.gov.